Loading...
Back to narrative

Next Generation Cell Therapy Will Expand Global Patient Access

LEGN logo
LEGN
AnalystConsensusTarget
Not Invested
Published 01 May 2025

Update shared on10 Sep 2025

Fair value Increased 0.25%
AnalystConsensusTarget's Fair Value
US$77.46
59.1% undervalued intrinsic discount
10 Sep
US$31.70
Loading
1Y
-36.6%
7D
-1.1%

Analysts raised Legend Biotech's price target slightly to $77.46, citing growing conviction in Carvykti's commercial success and the company's strengthening leadership in cell therapy, which supports expectations for sustained growth.


Analyst Commentary


  • Carvykti has rapidly become the most successful CAR T-cell therapy on the market.
  • Bullish analysts view Carvykti as poised to be a multi-billion-dollar franchise.
  • Increased conviction in Legend Biotech’s long-term market leadership in cell therapy.
  • Strong commercial execution and adoption trends for Carvykti.
  • Raised price target reflects expectations for significant growth and upside potential.

What's in the News


  • Legend Biotech is considering a second stock listing outside the U.S., with potential venues including Hong Kong, Singapore, and London; such a move could potentially boost the company’s valuation, especially in Hong Kong (Bloomberg).
  • The company announced the appointment of Carlos Santos as Chief Financial Officer; Santos brings extensive finance leadership experience from AstraZeneca, Novartis/Alcon, and Intel, and will focus on strengthening Legend's balance sheet and driving profitability (Key Developments).
  • Legend updated product labeling and reduced monitoring requirements for its BCMA- and CD19-directed CAR T cell therapies, reflecting accumulated real-world safety data and post-approval surveillance (Key Developments).
  • As of June 30, 2025, over 6,500 patients have been treated with Legend’s CARVYKTI (cilta-cel) in clinical and commercial settings, demonstrating broadening adoption of its cell therapy platform (Key Developments).
  • The European Medicines Agency recommended including warnings for CARVYKTI regarding potential late-onset immune-mediated enterocolitis and rare cases of gastrointestinal perforation, some with fatal outcomes (Key Developments).

Valuation Changes


Summary of Valuation Changes for Legend Biotech

  • The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $77.27 to $77.46.
  • The Future P/E for Legend Biotech remained effectively unchanged, moving only marginally from 27.80x to 27.87x.
  • The Net Profit Margin for Legend Biotech remained effectively unchanged, at 27.58%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.